Loading...
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
Yao, J Fazio, N Singh, S Buzzoni, R Carnaghi, C Wolin, E Tomasek, J Raderer, M Lahner, H Voi, M
Yao, J
Fazio, N
Singh, S
Buzzoni, R
Carnaghi, C
Wolin, E
Tomasek, J
Raderer, M
Lahner, H
Voi, M
Citations
Altmetric:
Abstract
Effective systemic therapies for patients with advanced, progressive neuroendocrine tumours of the lung or gastrointestinal tract are scarce. We aimed to assess the efficacy and safety of everolimus compared with placebo in this patient population.
Description
Date
2015-12-15
Publisher
Collections
Keywords
Type
Article
Citation
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. 2015: Lancet